Curcumin and inflammatory bowel diseases: from in vitro studies to clinical trials

Fallahi, Farzaneh and Borran, Sarina and Ashrafizadeh, Milad and Zarrabi, Ali and Pourhanifeh, Mohammad Hossein and Khaksary Mahabady, Mahmood and Sahebkar, Amirhossein and Mirzaei, Hamed (2021) Curcumin and inflammatory bowel diseases: from in vitro studies to clinical trials. Molecular Immunology, 130 . pp. 20-30. ISSN 0161-5890 (Print) 1872-9142 (Online)

Full text not available from this repository. (Request a copy)


Inflammatory bowel diseases (IBDs) may result from mutations in genes encoding for innate immunity, which can lead to exacerbated inflammatory response. Although some mono-targeted treatments have developed in recent years, IBDs are caused through several pathway perturbations. Therefore, targeting all these pathways is difficult to be achieved by a single agent. Moreover, those mono-targeted therapies are usually expensive and may cause side-effects. These limitations highlight the significance of an available, inexpensive and multi-targeted dietary agents or natural compounds for the treatment and prevention of IBDs. Curcumin is a multifunctional phenolic compound that is known for its anti-inflammatory and immunomodulatory properties. Over the past decades, mounting experimental investigations have revealed the therapeutic potential of curcumin against a broad spectrum of inflammatory diseases including IBDs. Furthermore, it has been reported that curcumin directly interacts with many signaling mediators implicated in the pathogenesis of IBDs. These preclinical findings have created a solid basis for the assessment of the efficacy of curcumin in clinical practice. In clinical trials, different dosages e.g., 550 mg /three times daily-1month, and 1 g /twice times daily-6month of curcumin were used for patients with IBDs. Taken together, these findings indicated that curcumin could be employed as a therapeutic candidate in the treatment of IBDs. Moreover, it seems that overcome to current limitations of curcumin i.e., poor oral bioavailability, and poor oral absorption with using nanotechnology and others, could improve the efficacy of curcumin both in pre-clinical and clinical studies.
Item Type: Article
Uncontrolled Keywords: Anti-inflammation; Curcumin; Disease therapy; Herbal compound; Inflammatory bowel disease
Divisions: Faculty of Engineering and Natural Sciences > Academic programs > Biological Sciences & Bio Eng.
Faculty of Engineering and Natural Sciences
Sabancı University Nanotechnology Research and Application Center
Depositing User: Ali Zarrabi
Date Deposited: 19 Aug 2022 11:49
Last Modified: 19 Aug 2022 11:49

Actions (login required)

View Item
View Item